Brand Engagement Network (NASDAQ:BNAI) said it has entered into a Vendor Services Project Agreement with a unit of a leading global advertising agency to develop a custom artificial-intelligence engagement method for a top-10 global pharmaceutical company’s prescription drug.
The Los Angeles-based company, which trades on the Nasdaq under the ticker BNAI, said it expects to recognize about $250,000 in development revenue tied to two statements of work during the fourth quarter of 2025.
Monthly recurring license fees associated with the project are expected to begin in the first quarter of 2026, the company said.
Brand Engagement Network added that the new engagement project, alongside its exclusive Latin American licensing partnership and the launch of the Skye Salud AI healthcare venture in Mexico, could contribute positively to fourth-quarter 2025 results.
The company said the initiatives underscore growing adoption of its secure, healthcare-focused AI solutions across international markets.
The company has positioned its platform around compliant, privacy-focused AI tools tailored for regulated industries such as healthcare, as pharmaceutical companies and their marketing partners increasingly look to deploy AI-driven engagement models while maintaining strict data security standards.